Published in Int J Pancreatol on January 01, 2001
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. J Natl Cancer Inst (2017) 0.84
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology (2016) 0.80
Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget (2016) 0.75
Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation. Oncotarget (2017) 0.75
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet (1999) 8.91
HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet (1996) 5.43
A prokaryotic voltage-gated sodium channel. Science (2001) 4.56
A sperm ion channel required for sperm motility and male fertility. Nature (2001) 4.43
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol (2001) 2.24
Removal of endotoxin from recombinant protein preparations. Clin Biochem (1997) 1.95
Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med (1995) 1.87
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol (1998) 1.78
Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem (2002) 1.77
Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol Cell Biol (2001) 1.76
Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost (2012) 1.76
Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost (2003) 1.74
Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J Biol Chem (2001) 1.72
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer (2011) 1.69
The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas (1996) 1.68
Driver landmark and traffic sign identification in early Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.65
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60
A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol (2000) 1.58
Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene (2011) 1.50
Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood (2000) 1.48
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res (2001) 1.46
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45
Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. J Invest Dermatol (1997) 1.44
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41
Neurotrophins promote maturation of developing neuromuscular synapses. J Neurosci (1995) 1.41
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer (2004) 1.40
Driver route-following and safety errors in early Alzheimer disease. Neurology (2004) 1.40
Genetic polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) and risk of vitiligo in Han Chinese populations: a genotype-phenotype correlation study. Br J Dermatol (2014) 1.39
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys (1995) 1.39
Position-dependent linkages of fibronectin- integrin-cytoskeleton. Proc Natl Acad Sci U S A (2000) 1.35
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg (1996) 1.35
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
HIV risk behaviours of current sex workers attending syringe exchange: the experiences of women in five US cities. AIDS Care (1999) 1.32
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol (1998) 1.29
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27
Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis (2007) 1.25
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg (1994) 1.25
Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg (2000) 1.24
Reticulon proteins: emerging players in neurodegenerative diseases. Cell Mol Life Sci (2006) 1.23
Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res (1999) 1.23
Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res (1995) 1.21
Syringe exchange in the United States, 1996: a national profile. Am J Public Health (1999) 1.20
Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res (1998) 1.20
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol (1990) 1.20
Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res (1994) 1.19
Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol (2009) 1.18
Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res (1999) 1.18
Selenium deficiency increases the pathology of an influenza virus infection. FASEB J (2001) 1.17
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene (1999) 1.15
Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res (1996) 1.15
Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J Immunol (1993) 1.14
Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) (2015) 1.13
Comparison of the effect of monopolar and bipolar cauterization on skeletonized, dissected internal thoracic arteries. J Thorac Cardiovasc Surg (1995) 1.11
Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost (2012) 1.09
Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery (1995) 1.09
Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol (1997) 1.06
Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol (1994) 1.05
Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res (2000) 1.05
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res (2001) 1.05
Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res (1999) 1.04
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology (2012) 1.04
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens (2007) 1.04
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol (2001) 1.03
Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res (1999) 1.03
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg (2000) 1.02
DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res (1998) 1.01
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res (1996) 1.01
Syringe-exchange programs in the United States: where are we now? AIDS Public Policy J (1996) 1.01
Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer (2006) 1.01
Cytoplasmic accumulation of a normally mitochondrial malonyl-CoA decarboxylase by the use of an alternate transcription start site. Arch Biochem Biophys (1992) 1.00
Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med (1994) 1.00
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol (2002) 0.99